G. Herman, C. Stevens, K. van Dyck
Dec 1, 2005
Citations
22
Influential Citations
502
Citations
Quality indicators
Journal
Clinical Pharmacology & Therapeutics
Abstract
Sitagliptin (MK‐0431 [(2R)‐4‐oxo‐4‐(3‐[trifluoromethyl]‐5,6‐dihydro[1,2,4]triazolo[4,3‐a]pyrazin‐7[8H]‐yl)‐1‐(2,4,5‐trifluorophenyl)butan‐2‐amine]) is an orally active, potent, and selective inhibitor of dipeptidyl peptidase IV (DPP‐IV) currently in phase III development for the treatment of type 2 diabetes.